MDM2 and central nervous system cancer: Mechanistically, PDIA3P1 promoted PMT by disrupting the C/EBPβ/MDM2 complex to inhibit the ubiquitination of C/EBPβ, enabling glioma cells to obtain stronger TMZ therapy resistance.